Log in

Relevant bibliographies by topics / Coronary heart disease – Chemotherapy

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Coronary heart disease – Chemotherapy'

Author: Grafiati

Published: 4 June 2021

Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Coronary heart disease – Chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Coronary heart disease – Chemotherapy"

1

Palmer, S. C., J. Carver, L. Jacobs, K. H. Schmitz, C. Fung, E. Mohler, and D. J. Vaughn. "Assessment of coronary heart disease risk in testicular cancer survivors." Journal of Clinical Oncology 24, no. 18_suppl (June 20, 2006): 4592. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.4592.

Full text

Abstract:

4592 Background: Testicular cancer survivors (TCS) who receive cisplatin-based chemotherapy (CBCT) are reported to have an increased risk of coronary heart disease (CHD) compared to chemo-naive TCS (J Clin Oncol 21:1513–1523, 2003). We hypothesized that TCS treated with CBCT would demonstrate abnormal objective measures of future CHD risk compared to chemo-naive TCS. Methods: TCS ≥ 2 years from diagnosis underwent evaluation using established objective measures predictive of future CHD risk: body mass index (BMI), Framingham relative risk (RR), flow-mediated endothelium-dependent vasodilation of the brachial artery (FMD), carotid artery intima-media thickness (IMT), serum intercellular adhesion molecule-1 (ICAM-1), and high sensitivity C-reactive protein (hs-CRP). Data were analyzed using parametric and non-parametric statistics as appropriate. Results: 30 TCS who received CBCT and 20 chemo-naive TCS were recruited. The mean age and time from diagnosis were similar between the 2 groups. Both groups demonstrated elevated BMI, increased Framingham RR, and impaired FMD, consistent with an increased risk of CHD. However, there were no statistically significant differences in these measures between the two groups. Carotid IMT, ICAM-1, and hs-CRP were not significantly abnormal and these measures also did not differ between the two groups. Conclusions: TCS demonstrate abnormal objective measures of CHD risk in both CBCT-treated and chemo-naive groups. These data suggest that behavioral interventions to modify CHD risk should target all TCS independent of chemotherapy status. All values reported are mean ± standard deviation [Table: see text] No significant financial relationships to disclose.

APA, Harvard, Vancouver, ISO, and other styles

2

Сергеева, N. Sergeeva, Коломиец, V. Kolomiets, Маль, G. Mal, Алыменко, and M. Alymenko. "Evaluation of Spent Pharmacotherapy in the Patients with Coronary Heart Disease Associated with Pulmonary Tuberculosis by means of the Neural Network." Journal of New Medical Technologies 21, no. 4 (October 8, 2014): 108–12. http://dx.doi.org/10.12737/7281.

Full text

Abstract:

Current, the programs of mass prevention of the cardiovascular diseases, based on preventive medicinal correction of risk factors of cardiovascular diseases, such as hyperlipidemia, arterial hypertension, diabetes mellitus, are developed and realized. Pulmonary tuberculosis influences on state of blood system, which can be considered as functional disorders of the cardiovascular system caused by tuberculosis. These violations caused by concomitant tuberculosis lung diseases, such as cardiovascular and other diseases of the respiratory system. Specific (tuberculosis) damages of the heart and blood vessels are rare and currently their influence on pathomorphosis of tuberculosis isn’t expressed. Modern schemes of treatment of coronary heart disease and hypertension are also applicable to patients with Pulmonary tuberculosis. Effective treatment of coronary heart disease and hypertension in patients with tuberculosis by means of the drugs, allows to normalize the function of the cardiovascular system and to carry out long-chemotherapy by anti-TB drugs and cures of tuberculosis. The study showed the ability to predict the degree of lipid-lowering effect in patients with coronary heart disease in combination with infiltrative tuberculosis of the lungs that can provide the right choice of drug in lipid-lowering therapy.

APA, Harvard, Vancouver, ISO, and other styles

3

Bachmeyer, Claude, Hervé Joly, and Roland Jorest. "Early Myocardial Infarction during Chemotherapy for Testicular Cancer." Tumori Journal 86, no. 5 (September 2000): 428–30. http://dx.doi.org/10.1177/030089160008600513.

Full text

Abstract:

A 36-year-old man with testicular cancer had an acute myocardial infarction during the first course of chemotherapy with bleomycin, etoposide and cisplatin. Since the patient had no significant risk factors for coronary heart disease, the infarction was likely to be attributable to the chemotherapy regimen. The physiopathological mechanisms of this causal relationship are discussed here.

APA, Harvard, Vancouver, ISO, and other styles

4

Ozben, Beste, Ramazan Kurt, Huseyin Oflaz, Murat Sezer, Mert Basaran, Taner Goren, and Sabahattin Umman. "Acute Anterior Myocardial Infarction After Chemotherapy for Testicular Seminoma in a Young Patient." Clinical and Applied Thrombosis/Hemostasis 13, no. 4 (October 2007): 439–42. http://dx.doi.org/10.1177/1076029607303334.

Full text

Abstract:

Testicular cancer is the most common solid tumor among young men aged 15 to 35 years. Combination chemotherapy with cisplatin, etoposide, and bleomycin remains the mainstay of treatment. We present a 27-year-old man who presented with an acute anterior myocardial infarction during the second course of chemotherapy for seminoma. Because the patient had no significant risk factors for coronary heart disease, the infarction was likely caused by the chemotherapy regimen.

APA, Harvard, Vancouver, ISO, and other styles

5

Hader, Shelby N., Natalya Zinkevich, Laura E. Norwood Toro, Alison J. Kriegel, Amanda Kong, Julie K. Freed, David D. Gutterman, and Andreas M. Beyer. "Detrimental effects of chemotherapy on human coronary microvascular function." American Journal of Physiology-Heart and Circulatory Physiology 317, no. 4 (October 1, 2019): H705—H710. http://dx.doi.org/10.1152/ajpheart.00370.2019.

Full text

Abstract:

Chemotherapy (CT) is a necessary treatment to prevent the growth and survival of cancer cells. However, CT has a well-established adverse impact on the cardiovascular (CV) system, even years after cessation of treatment. The effects of CT drugs on tumor vasculature have been the focus of much research, but little evidence exists showing the effects on the host microcirculation. Microvascular (MV) dysfunction is an early indicator of numerous CV disease phenotypes, including heart failure. The goal of this study was to evaluate the direct effect of doxorubicin (Dox) on human coronary MV function. To study the effect of CT on the cardiac MV function, flow-mediated dilation (FMD), pharmacologically-induced endothelial dependent dilation to acetylcholine (ACh), and smooth muscle-dependent dilation to papaverine were investigated. Vessels were freshly isolated from atrial appendages of adult patients undergoing cardiopulmonary bypass surgery or from cardiac tissue of pediatric patients, collected at the time of surgery to repair congenital heart defects. Isolated vessels were incubated in endothelial culture medium containing vehicle or Dox (100 nm, 15–20 h) and used to measure dilator function by video microscopy. Ex vivo treatment of adult human coronary microvessels with Dox significantly impaired flow-mediated dilation (FMD). Conversely, in pediatric coronary microvessels, Dox-induced impairment of FMD was significantly reduced in comparison with adult subjects. In both adult and pediatric coronary microvessels, ACh-induced constriction was reversed into dilation in the presence of Dox. Smooth muscle-dependent dilation remained unchanged in all groups tested. In vessels from adult subjects, acute treatment with Dox in clinically relevant doses caused significant impairment of coronary arteriolar function, whereas vessels from pediatric subjects showed only marginal impairment to the same stressor. This interesting finding might explain the delayed onset of future adverse CV events in children compared with adults after anthracycline therapy. NEW & NOTEWORTHY We have characterized, for the first time, human microvascular responses to acute ex vivo exposure to doxorubicin in coronary vessels from patients without cancer. Our data show an augmented impairment of endothelial function in vessels from adult subjects compared with pediatric samples.

APA, Harvard, Vancouver, ISO, and other styles

6

Zhang, Dingguo, Liansheng Wang, and Zhijian Yang. "Recurrent Syncope Associated with Lung Cancer." Case Reports in Medicine 2015 (2015): 1–4. http://dx.doi.org/10.1155/2015/309784.

Full text

Abstract:

Syncope is an important problem in clinical practice with many possible causes that might be misdiagnosed. We present an unusual case of syncope, which has a normal chest X-ray. Exercise EKG and coronary angioplasty results confirmed the existence of serious coronary heart disease. The patient was treated with coronary stent transplantation. However, scope occurred again and the elevated tumor makers cytokeratin-19-fragment and neuron-specific enolase revealed the bronchogenic carcinoma, which was confirmed by enhanced CT examination. The treatment of carcinoma by chemotherapy was indeed sufficient for prompt elimination of the syncope symptoms.

APA, Harvard, Vancouver, ISO, and other styles

7

Daher, Iyad N., Jose Banchs, Syed Wamique Yusuf, Elie Mouhayar, Jean-Bernard Durand, and Gregory Gladish. "Impact of Cardiac Computed Tomographic Angiography Findings on Planning of Cancer Therapy in Patients with Concomitant Structural Heart Disease." Cardiology Research and Practice 2011 (2011): 1–7. http://dx.doi.org/10.4061/2011/268058.

Full text

Abstract:

Background. Exclusion of underlying coronary artery disease (CAD) is essential in the diagnosis of chemotherapy-induced cardiomyopathy. Presence and severity of CAD can also impact the choice of therapy in cancer patients. The value of cardiac computed tomographic angiography (CCTA) in this setting has not been reported.Methods. We collected data on the clinical presentation and indications for CCTA performed from January to December 2008 at the University of Texas MD Anderson Cancer Center (MDACC). All examinations were performed using a 64-detector scanner. CCTA results and subsequent treatment decisions were examined.Results. A total of 80 patients underwent CCTA during the study period for the following indications (not mutually exclusive): cardiomyopathy of unknown etiology in 33 pts (41.3%), chest pain in 32 (40.0%), abnormal stress test in 16 (20.0%), abnormal cardiac markers in 8 (10.0%), suspected cardiac mass or thrombus in 7 (8.8%). Chemotherapy-induced cardiomyopathy was diagnosed in 18 pts (22.5%). Severe CAD was detected in 22 pts (27.5%); due to concomitant advanced cancer or patient refusal, only 12 underwent coronary angiogram. Of these, 4 pts (5% of total) underwent coronary artery bypass grafting. A total of 41 pts (51.3%) had their cancer management altered based on CCTA findings.Conclusion. CCTA is useful in evaluating cancer pts with structural heart disease and can have an impact on the management of cancer and cardiac disease.

APA, Harvard, Vancouver, ISO, and other styles

8

van Leeuwen, Flora E., and Andrea K. Ng. "Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment." Hematology 2016, no. 1 (December 2, 2016): 323–30. http://dx.doi.org/10.1182/asheducation-2016.1.323.

Full text

Abstract:

Abstract Long-term survivors of Hodgkin lymphoma (HL) experience several late adverse effects of treatment, with second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs) being the leading causes of death in these patients. Other late effects have also been identified, such as pulmonary dysfunction, endocrinopathies (thyroid dysfunction, infertility), neck muscle atrophy, and persistent fatigue. HL survivors have two- to fourfold increased risks to develop SMNs and CVD compared with the general population. With respect to SMNs, radiotherapy is associated with 1.5- to 15-fold increased risk of solid malignancies. The relative risk (RR) of solid tumors increases steadily with increasing follow-up time from 5 to 15 years since radiotherapy, and remains elevated for at least 40 years. The RR of solid SMNs increases strongly with younger age at first treatment. Risks of lung, breast, and gastrointestinal (GI) cancers increase with higher radiation dose. Alkylating agent chemotherapy, especially procarbazine, does not only increase risk of leukemia but also of solid malignancies, in particular, cancers of the lung and GI tract. In contrast, gonadotoxic chemotherapy decreases the risk of radiation-associated breast cancer, through induction of premature menopause. Smoking appears to multiply the radiation- and chemotherapy-associated risks of lung cancer. Both radiotherapy and chemotherapy for HL may cause cardiovascular toxicity. Radiotherapy increases the risk of coronary heart disease, valvular heart disease, congestive heart failure (HF), and pericarditis, whereas anthracycline-containing chemotherapy increases the risks of HF and valvular heart disease. Cardiovascular toxicity following radiotherapy is usually observed from 5 to at least 35 years after therapy, whereas anthracycline-related toxicity is already observed during treatment, up to at least 25 years. The joint effects of anthracyclines, radiotherapy, and conventional cardiovascular risk factors (eg, hypertension, smoking, and physical inactivity) appear to be additive rather than multiplicative. HL survivors need lifelong risk-based screening for selected SMNs and CVDs. Furthermore, preventive strategies should include lifestyle and drug-based interventions to minimize exposure to conventional risk factors for cancer and CVD.

APA, Harvard, Vancouver, ISO, and other styles

9

Chaulin, A. M., and D. V. Duplyakov. "Increased natriuretic peptides not associated with heart failure." Russian Journal of Cardiology 25 (January 11, 2021): 4140. http://dx.doi.org/10.15829/1560-4071-2020-4140.

Full text

Abstract:

Natriuretic peptides (NPs) are key diagnostic and prognostic biomarkers for patients with heart failure (HF). The main mechanism for increasing serum NP levels, which is characteristic of heart failure, is secretion in response to myocardial wall distention. At the same time, according to Russian and foreign literature, an increase in NPs is reported in a number of many other conditions that are not associated with HF. The study of these causes and mechanisms is necessary to improve the differential diagnosis of HF.This article discusses the mechanisms of increasing NPs and their diagnostic value in heart failure, as well as a number of other conditions, such as acute coronary syndrome and coronary artery disease, atrial fibrillation, exercise, kidney failure, taking cardiotoxic drugs (chemotherapy) and sacubitril/valsartan. The article also provides data on identifying NPs in non-invasively obtained biological fluids (urine and oral fluid).

APA, Harvard, Vancouver, ISO, and other styles

10

Karev, E. A., S. L. Verbilo, E. G. Malev, M. N. Prokudina, P. A. Mochalov, E. A. Bobrova, N. P. Malinina, and A. V. Kozlenok. "Myocardial strain echocardiographic assessment: from theory to practice." Translational Medicine 7, no. 6 (December 18, 2020): 16–28. http://dx.doi.org/10.18705/2311-4495-2020-7-6-16-28.

Full text

Abstract:

Assessment of systolic and diastolic ventricular function is one of the main goals of echocardiography. Nevertheless, some patients require data beyond standard echocardiographic protocol for making more precise clinical decision and prognosis determination. The spectrum of novel parameters, including myocardial strain and strain rate, provides more comprehensive evaluation of the initial changes in myocardium in a variety of clinical conditions. New methods of quantifying the systolic function of left and right ventricles can be applied in patients with arterial hypertension, coronary heart disease, hypertrophic and dilated cardiomyopathies, also in patients with valvular heart disease such as aortic stenosis, aortic and mitral insufficiency. Besides strain analysis in patients with myocardial storage diseases, patients on cardiotoxic chemotherapy and patients with heart transplant turned out to be a specific niche for the method. Here, we provide the possibilities of strain analysis in variable heart pathologies in clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Coronary heart disease – Chemotherapy"

1

Dorn, Karen Toft. "Circulatory, hormonal, and metabolic effects of arbutamine compared to exercise in persons with known or suspected coronary artery disease." Diss., Virginia Tech, 1994. http://hdl.handle.net/10919/38284.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dane-Stewart, Cheryl Ann. "Postprandial lipoprotein metabolism in patients at high risk of coronary artery disease : effects of statin therapy." University of Western Australia. School of Medicine and Pharmacology, 2003. http://theses.library.uwa.edu.au/adt-WU2004.0061.

Full text

Abstract:

[Formulae and special characters can only be approximated here. Please see the pdf version of the abstract for an accurate reproduction.] Atherosclerosis is a common degenerative disease in which the clinical manifestations are often through stroke or myocardial infarction. Some of the established risk factors for atherosclerosis include elevated plasma low-density lipoprotein (LDL)-cholesterol levels, obesity, diabetes mellitus (DM) and cigarette smoking. Of the risk factors, an elevation in plasma LDL is one of the most established and the most researched. This is partly a consequence of the deposition of cholesterol within arterial intima being a crucial step in the progression of atherosclerosis, combined with the finding that LDL particles are a major transporter of cholesterol in circulation. Recently there is increasing evidence showing a role of the other major transporter of cholesterol in circulation, chylomicron remnants, in the progression of atherosclerosis. The notion of atherosclerosis as a postprandial phenomenon has been further substantiated by the emergence of evidence showing a direct role of chylomicron remnants in arterial cholesterol deposition. Based on evidence that chylomicron remnants are proatherogenic, the suggestion arises that accumulation of postprandial lipoproteins in plasma may add another dimension of risk to the development of coronary artery disease (CAD). This thesis tests the general hypothesis that individuals with or at high risk of CAD have postprandial dyslipidaemia and that this metabolic abnormality is correctable with a class of lipid-lowering drugs called statins. To test the hypothesis, clinical studies were conducted in normolipidaemic CAD patients, heterozygous familial hypercholesterolaemia (FH) and postmenopausal women with type 2 DM. Determination of postprandial dyslipidaemia by comparison with control populations were conducted initially in each patient group (Studies 1, 3 and 5), followed by intervention studies investigating possible modulation of the dyslipidaemia with a statin (Studies 2, 4 and 6). Six observation statements based on case-control comparisons of postprandial lipaemia in patients with or at risk of CAD and the effects of statins on postprandial dyslipidaemia in the patient groups were derived from the general hypothesis. The observation statements were examined in the individual studies described below. Postprandial lipoprotein metabolism was assessed using a number of methods. For comparison of postprandial lipaemia in Studies 1 and 2, a classic oral fat challenge was utilised. As markers of chylomicrons and chylomicron remnants, retinyl palmitate and triglyceride were measured postprandially as well as apolipoprotein (apo) B48 concentrations, a specific marker of intestinal lipoproteins. ApoB48 was also measured in the fasting state and found to predict the postprandial responses of retinyl palmitate, triglyceride and apoB48. This suggested that fasting measurement of apoB48 could be used as a simple indicator of postprandial dyslipidaemia. Consequently for Studies 3 - 6, fasting apoB48 measurements were used as primary markers of postprandial dyslipidaemia. Other markers for chylomicrons and their remnants utilised were fasting plasma concentrations of remnant-like particle-cholesterol (RLP-C) and apoC-III. As well as these static markers, chylomicron remnant catabolism was measured using a stable isotope breath test. The breath test involves the intravenous injection of a chylomicron remnant-like emulsion labelled with ¹³C-oleate and measurement of enriched ¹³CO2 in expired breath by isotope ratio mass spectrometry. The fractional catabolic rate (FCR) of the injected emulsion was subsequently calculated using multi-compartmental modeling (SAAM II). The studies are presented in this thesis as published and unpublished works. In Study 1, postprandial lipoprotein metabolism was compared between 18 normolipidaemic CAD patients (cholesterol 4.54 ± 0.12 mmol/L, triglyceride 1.09 ± 0.16) with 13 asymptomatic healthy controls using an oral fat challenge. Normolipidaemic CAD patients had higher postprandial area-under-curve (AUC) for triglyceride (+34%, p=0.019), retinyl palmitate (+74%, p=0.032) and apoB48 (+36%, p<0.001). Fasting apoB48 was also higher (+41%, p=0.001) and found to correlate significantly with AUC of triglyceride (p=0.017), retinyl palmitate (p=0.001) and apoB48 (p<0.001). The data suggest that normolipidaemic CAD patients have increased concentrations of intestinal lipoproteins in the fasting and postprandial state. In addition to these findings, significant correlations of fasting apoB48 with postprandial markers (p<0.02) suggests the fasting marker to be a simpler surrogate marker for the degree of total postprandial lipaemia. Study 2 investigated the effect of atorvastatin treatment on postprandial dyslipidaemia found in the 18 near-normolipidaemic CAD patients from Study 1. The trial was conducted in a randomised, placebo-controlled design, using oral fat challenges before and after 12-weeks atorvastatin/placebo treatment. Compared with the placebo group, atorvastatin decreased the total postprandial AUC for iii triglyceride (-22%, p=0.05) and apoB48 (-34%, p=0.013). Fasting markers of apoB48 (-35%, p=0.019) and RLP-C (-36%, p=0.032) also decreased significantly. Atorvastatin was also found to increase LDL-receptor activity by +218% (p<0.001) as reflected in binding studies. The data suggest atorvastatin reduces the fasting levels of intestinal lipoproteins as well as total postprandial lipaemia, but without acute dynamic changes in postprandial lipaemia. The reduction in fasting and total postprandial lipoprotein levels could be partly attributed to an increase in LDL-receptor mediated removal from circulation. In Study 3, postprandial lipaemia was compared in 15 heterozygous FH patients with 15 healthy controls. FH patients had higher fasting concentrations of apoB48 (+56%, p<0.001) and RLP-C (+48%, p=0.003). The elevation in these fasting markers of chylomicrons and their remnants suggests FH patients have postprandial dyslipidaemia due to an accumulation of these particles in plasma. Study 4 examined the effects of long- (> 6 months) and short-term (4 weeks) simvastatin treatment on modulating postprandial dyslipidaemia found in the 15 FH patients from Study 3. Short- and long-term simvastatin treatment decreased the fasting concentrations of apoB48 (-29% and 15% respectively, p<0.05) and RLP-C (both -38%, p<0.001), but did not significantly alter the FCR of the injected chylomicron remnant-like emulsion. The data suggest that in heterozygous FH both long- and short-term simvastatin treatments decrease the fasting markers of postprandial lipoproteins by mechanisms that may not be mediated via processes differentiated by the 13CO2 breath test. This implies that the effect on postprandial lipaemia may be from a decrease in production and/or a possible increase in catabolism of triglyceride-rich lipoproteins (TRLs). In Study 5, postprandial lipaemia was compared in 24 postmenopausal women age and body mass index matched with 14 postmenopausal women with type 2 DM. Postmenopausal diabetic women were found to have higher fasting concentrations of apoB48 (+21%, p=0.021) and apoC-III (+16%, p=0.042) as well as lower FCR of the chylomicron remnant-like emulsion (-50%, p<0.001). The data suggest that postmenopausal diabetic women have postprandial dyslipidaemia, and that this is due to delayed catabolism of chylomicron remnants. Study 6 was an hypothesis-generating exercise examining the effects of 4-weeks pravastatin treatment on postprandial dyslipidaemia found in 7 postmenopausal women with type 2 DM from Study 5. Although plasma LDL-cholesterol was reduced (-19%, p=0.028), there were no significant effects found on fasting apoB48 concentrations (-12%, p=0.116) or the FCR of the chylomicron remnant-like emulsion (+38%, p=0.345). A larger sample size of patients and/or treatment with a more potent statin at a dosage known to affect chylomicron remnant metabolism would be required to demonstrate a significant reduction in postprandial dyslipidaemia in postmenopausal women with type 2 DM. The results of the above mentioned studies combined support the general hypothesis that postprandial dyslipidaemia is a feature of patients with or at risk of CAD. This defect may be demonstrated using fasting apoB48 as an indicator of the degree of postprandial lipaemia. Postprandial dyslipidaemia may reflect a reduction in catabolism, as suggested with the breath test in type 2 DM, and/or an over overproduction of chylomicrons. Both these mechanisms would also increase competition for lipolysis and clearance pathways between hepatically and intestinally-derived lipoproteins. The exact mechanisms by which postprandial dyslipidaemia occurs are yet to be determined. Statins appear to improve defective postprandial lipaemia in patients with or at risk of CAD, which is in agreement with the general hypothesis. The effectiveness of a statin is dependant on their potency in inhibiting cholesterol biosynthesis and increasing receptor mediated clearance of LDL and chylomicron remnants. The studies conducted in this thesis show that postprandial dyslipidaemia can be reduced by statins but not to the extent demonstrated in controls. However, the demonstrated reduction in fasting and total postprandial lipaemia translates to a lowering in overall arterial exposure to circulating proatherogenic particles. The elevation in fasting and postprandial levels of proatherogenic chylomicron remnants found in the patient groups described in this thesis indicates another dimension to their risk of coronary disease. The reductions in the overall levels of proatherogenic particles in patients with or at high CAD risk, infers a possible reduction in the risk of coronary disease in these patients.

APA, Harvard, Vancouver, ISO, and other styles

3

Brouilette, Scott Wayne. "Telomeres and coronary heart disease." Thesis, University of Leicester, 2004. http://hdl.handle.net/2381/29899.

Full text

Abstract:

Using mean telomere length as a marker of biological age, I show that: 1. Subjects with premature myocardial infarction (MI) have significantly shorter telomeres than age-sex matched, healthy, controls. The mean telomere length in MI subjects was similar to controls almost 11 years older. 2. Healthy young adult children of families with a strong history of premature MI have shorter telomeres than age matched children of families without such a history. 3. Shorter telomere lengths are associated with increase risk of subsequent CHD events in a prospective study. This analysis was carried out on samples collected in the West of Scotland Coronary Prevention Study (WOSCOPS). This randomised blinded trial was designated to examine the benefits of statin treatment on preventing CHD and showed a 30% reduction of events in those treated with pravastatin. Interestingly, my analysis showed that this benefit of statin is only seen in those subjects at higher risk of CHD based on their telomere length.;As the final part of the thesis I carried out a quantitative linkage trait (QTL) analysis in sib-pairs in an attempt to identify genetic loci regulating telomere length. I report the mapping of a major QTL on chromosome 12 that determines almost 50% of the inter-individual variation in mean telomere length.;These findings support a novel "telomere" hypothesis of CHD. They indicate that telomere biology is intimately linked to the genetic aetiology and pathogenesis of CHD. Specifically, the findings suggest that (i) those individuals born with shorter telomeres may be at increased risk of CHD (ii) rather than individual genes, a more global structural property of the genetic material may explain the familial basis of CHD (iii) variation in telomere length may explain, in part, the variable age of onset of CHD. The findings provide several new avenues for future research.

APA, Harvard, Vancouver, ISO, and other styles

4

Lee, Chi-hang. "Microvascular obstruction following percutaneous coronary intervention for coronary artery disease." Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B43278723.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Danesh, John. "Chronic infection and coronary heart disease." Thesis, University of Oxford, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.326020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kounali, Daphne. "Early growth and coronary heart disease." Thesis, University of Southampton, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436926.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Heiser, Claire Anne. "Personality predictors of coronary heart disease." Thesis, Virginia Polytechnic Institute and State University, 1985. http://hdl.handle.net/10919/50027.

Full text

Abstract:

Fifty percent of the diagnosed cases of coronary heart disease in the United States are of unknown etiology. This study proposed that five personality traits— achievement, dominance, aggression, succorance and Critical Parent—differentiate individuals with coronary heart disease manifestations. The ultimate goal of this research was to formulate a predictive profile of at-risk individuals of developing coronary heart disease. Cardiac rehabilitation units' participants from across the United States were recruited as subjects. Randomly selected cardiac rehabilitation units were sent an initial letter inquiring whether their staff would be willing to participate in the study by administering the instruments to their participants. Eight units from each of the 50 states were contacted. A total of fourteen units agreed to participate. One hundred sixty-nine subjects completed the Demographic Data Questionnaire and the Adjective Check List. Five scale scores, representing the five personality differentials, were analyzed. Comparison of the male subject population (n=135) and the male normative population (n=198) revealed no significant differences in terms of the five traits. Comparison of diagnostic subgroups of the subject population also revealed no significant differences. It was concluded that the subject population did not differ significantly from the normative population in terms of the five traits assess by the instrument used. The goal of a predictive profile was not realized due to this lack of findings.
Master of Science
incomplete_metadata

APA, Harvard, Vancouver, ISO, and other styles

8

Lee, Chi-hang, and 李志恆. "Microvascular obstruction following percutaneous coronary interventionfor coronary artery disease." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43278723.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Zapanta, Laurence (Laurence F. ). "Heart rate variability in mice with coronary heart disease." Thesis, Massachusetts Institute of Technology, 2005. http://hdl.handle.net/1721.1/34118.

Full text

Abstract:

Thesis (S.M.)--Massachusetts Institute of Technology, Dept. of Electrical Engineering and Computer Science, 2005.
Includes bibliographical references (leaves 69-71).
Heart rate variability (HRV), the beat-to-beat fluctuation of the heart rate, is a non-invasive test that measures the autonomic regulation of the heart. Assessment of HRV has been shown to predict the risk of mortality in patients after an acute myocardial infarction. Recently, the Krieger lab at MIT developed genetically engineered double knockout (dKO) mice that develop coronary artery disease accompanied by spontaneous myocardial infarctions and die at a very young age. This thesis investigated whether HRV could function as a prognostic indicator in the dKO mouse. A novel method for estimating physiological state of the mouse from the electrocardiogram using an innovative activity index was developed in order to compare HRV variables at different times while controlling for physiologic state. Traditional time and frequency domain variables were used to assess the prognostic power of HRV. Results have shown that none of the HRV variables were helpful in predicting mortality in the dKO mice. Mean heart rate showed some prognostic power, but it was not consistent in all the dKO mice. Finally, the activity index developed in this thesis provided a reliable metric for activity in mice as validated by a camera with motion detection.
by Laurence Zapanta.
S.M.

APA, Harvard, Vancouver, ISO, and other styles

10

Rose, Edward Leslie. "Coronary heart disease in patients with peripheral vascular disease." Thesis, University of Oxford, 1991. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.305544.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Coronary heart disease – Chemotherapy"

1

International, Symposium on Molsidomine (1984 Düsseldorf Germany). Ischemic heart disease and heart failure: Advances in treatment with molsidomine. Munich ; Baltimore: Urban & Schwarzenberg, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

R, Lichtlen Paul, ed. New therapy of ischaemic heart disease and hypertension: Proceedings of the symposium held in Geneva, 18-20 April 1985. Amsterdam: Excerpta Medica, 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Workshop on Nisoldipine in Coronary Artery Diseases and Myocardial Infarction (1992 London). Workshop on nisoldipine in coronary artery diseases and myocardial infarction: Papers presented at a workshop held in London, April 8, 1992, during the International Conference on Acute Myocardial Infarction. New York: Raven Health Care Communications, 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Questions from the heart: Answers to 100 questions about Chelation therapy, a safe alternative to bypass surgery. Charlottesville, Va: Hampton Roads Pub., 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kendall, Martin J. Preventing coronary artery disease: Cardioprotective therapeutics in practice. 2nd ed. London: Martin Dunitz, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

N, Cohn Jay, and Rittinghausen R, eds. Mononitrates: [International Symposium on Mononitrates, Montreux, Switzerland, June 14-16, 1984]. Berlin: Springer-Verlag, 1985.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Schneeweiss, Adam. Advances in nitrate therapy. 2nd ed. Berlin: Springer-Verlag, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Schneeweiss, Adam. Advances in nitrate therapy. Berlin ; New York: Springer-Verlag, 1988.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Cranton, Elmer M. Xiang tong bo zai shuo bu: Gen zhi wan zheng de qu du liao fa = Bypassing bypass surgery. [Xianggang]: Tian chuang chu ban she you xian gong si, 2014.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Clopidogrel response in acute coronary syndrome: Clinical implications and emerging therapies. Hauppauge, N.Y: Nova Science Publishers, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Coronary heart disease – Chemotherapy"

1

Slanina, Joachim, Karl Henne, Norbert Hodapp, Gisela Moog, and Hermann Frommhold. "Cardiotoxicity After Megavoltage Irradiation and Chemotherapy for Hodgkin’s Disease with Special Emphasis on Coronary Heart Disease Mortality — The Freiburg Experience 1940–1992." In Late Sequelae in Oncology, 191–95. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-46794-3_25.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bergersen, Lisa, Susan Foerster, Audrey C. Marshall, and Jeffery Meadows. "Coronary Angiography." In Congenital Heart Disease, 143–50. Boston, MA: Springer US, 2009. http://dx.doi.org/10.1007/978-0-387-77292-9_23.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Abdelhafiz, Ahmed H. "Coronary heart disease." In Diabetes in Old Age, 67–83. Chichester, UK: John Wiley & Sons, Ltd, 2017. http://dx.doi.org/10.1002/9781118954621.ch7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Schenck-Gustafsson, Karin. "Coronary Heart Disease." In Handbook of Clinical Gender Medicine, 190–205. Basel: KARGER, 2012. http://dx.doi.org/10.1159/000336385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kalmar, Jayne M., Brigid M. Lynch, Christine M. Friedenreich, Lee W. Jones, A. N. Bosch, Alessandro Blandino, Elisabetta Toso, et al. "Coronary Heart Disease." In Encyclopedia of Exercise Medicine in Health and Disease, 213–16. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_51.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Tsuboi, Hirohito, Katsunori Kondo, Hiroshi Kaneko, and Hiroko Yamamoto. "Coronary Heart Disease." In Social Determinants of Health in Non-communicable Diseases, 41–52. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-1831-7_5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Feuerstein, Michael, Elise E. Labbé, and Andrzej R. Kuczmierczyk. "Coronary Heart Disease." In Health Psychology, 317–80. Boston, MA: Springer US, 1986. http://dx.doi.org/10.1007/978-1-4899-0562-8_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Gorog, Diana. "Coronary Heart Disease." In The Interventional Cardiology Training Manual, 1–11. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-71635-0_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Whang, William. "Coronary Heart Disease." In Encyclopedia of Behavioral Medicine, 503–5. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4419-1005-9_396.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Whang, William. "Coronary Heart Disease." In Encyclopedia of Behavioral Medicine, 1–3. New York, NY: Springer New York, 2019. http://dx.doi.org/10.1007/978-1-4614-6439-6_396-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Coronary heart disease – Chemotherapy"

1

Poniewierski, M., M. Barthels, and H. Poliwoda. "THE SAFETY AND EFFICACY OF A LOW MOLECULAR WEIGHT HEPARIN (FRAGMIN) IN THE PREVENTION OF DEEP VEIN THROMBOSIS IN MEDICAL PATIENTS: A RANDOMIZED DOUBLE-BLIND TRIAL." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643224.

Full text

Abstract:

The safety and efficacy of 2500 anti-Factor Xa U of a low molecular weight heparin (Kabi 2165, Fragmin) subcutaneously once a day, and 5000 IU of standard unfractionated Heparin (KabiVitrum, Stockholm) subcutaneously twice daily as thromboprophylaxis was compared in 200 medical patients in a randomized double blind trial. According to the risk of DVT the patients were stratified before randomization in a high and low risk group. The high risk group consisted of 100 patients mainly with malignant diseases and/or previous history of thromboembolism, the low risk group of 100 patients with mainly myocardial infarction and/or coronary heart disease. The prophylaxis was given for seven to ten days. In 192 consecutive patients the clinical status and thermographic screening for DVT (leg temperature profiles, DeVeTherm) were daily evaluated. In two cases of suspected DVT and one case of suspected PE, the following phlebography or pulmonary scintigraphy were found to be negative. In the high risk group, one patient treated with Fragmin having a central venous catheter developed on day 10 symptoms of an arm vein thrombosis. There were no bleeding complications observed in either of the two treatment groups. Two patients with trombocytopenia (25.000 and 22.000/pl) due to chemotherapy and underlying malignant disease were successfully treated with Fragmin without developing any bleeding complications. In eight patients during Fragmin prophylaxis invasive diagnostic methods as heart catheterization, gastroscopy, bronchoscopy or spinal puncture were performed without noticing any bleeding events. 2500 anti-Factor Xa U of Fragmin gave plasma levels by anti-Factor Xa assay (S-2222, Kabi) of mean 0,1 U/ml when blood was sampled three to four hours after the subcutaneus application. There was no accumulation during the treatment periode observed.This study suggests that 2500 anti-Factor Xa U of Fragmin once daily is as safe and effective as 5000 IU of standard heparin twice daily in these medical patients. Especially in patients who need prophylaxis for a long time eg. with malignant disease, the once daily injection is welcomed.

APA, Harvard, Vancouver, ISO, and other styles

2

Lin, Shisong, Xiaodong Zhuang, Shiyun Huang, Yahui Liu, Linlin Shen, and Xinxue Liao. "Face Analysis for Coronary Heart Disease Diagnosis." In 2019 12th International Congress on Image and Signal Processing, BioMedical Engineering and Informatics (CISP-BMEI). IEEE, 2019. http://dx.doi.org/10.1109/cisp-bmei48845.2019.8966020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Pareek, Vishakha, and R. K. Sharma. "Coronary heart disease detection from voice analysis." In 2016 IEEE Students' Conference on Electrical, Electronics and Computer Science (SCEECS). IEEE, 2016. http://dx.doi.org/10.1109/sceecs.2016.7509344.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mangathayaru, Nimmala, B. Padmaja Rani, V. Janaki, Lakshmi Sowmya Kotturi, Manasa Vallabhapurapu, and G. Vikas. "Heart Rate Variability for Predicting Coronary Heart Disease using Photoplethysmography." In 2020 Fourth International Conference on I-SMAC (IoT in Social, Mobile, Analytics and Cloud) (I-SMAC). IEEE, 2020. http://dx.doi.org/10.1109/i-smac49090.2020.9243316.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Runjing, Zhou, and Li Keyang. "Fisher classifier in diagnosis of coronary heart disease." In 2011 4th International Congress on Image and Signal Processing (CISP). IEEE, 2011. http://dx.doi.org/10.1109/cisp.2011.6100787.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gonsalves, Amanda H., Fadi Thabtah, Rami Mustafa A. Mohammad, and Gurpreet Singh. "Prediction of Coronary Heart Disease using Machine Learning." In the 2019 3rd International Conference. New York, New York, USA: ACM Press, 2019. http://dx.doi.org/10.1145/3342999.3343015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Li Xia, Fu Yifei, Bai Jing, Tian xin, and Li Fangjie. "Complexity analysis on heart rate variability of coronary heart disease patients." In 2008 International Conference on Technology and Applications in Biomedicine (ITAB). IEEE, 2008. http://dx.doi.org/10.1109/itab.2008.4570590.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

MISCHIE, Niculina, and Adriana ALBU. "Artificial Neural Networks for Diagnosis of Coronary Heart Disease." In 2020 International Conference on e-Health and Bioengineering (EHB). IEEE, 2020. http://dx.doi.org/10.1109/ehb50910.2020.9280271.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Khatibi, Vahid, and Gholam Ali Montazer. "Coronary heart disease risk assessment using dempster-shafer theory." In 2009 14th International CSI Computer Conference (CSICC 2009) (Postponed from July 2009). IEEE, 2009. http://dx.doi.org/10.1109/csicc.2009.5349607.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Widiyaningtyas, Triyanna, Ilham Ari Elbaith Zaeni, and Putri Yula Wahyuningrum. "Self-Organizing Map (SOM) For Diagnosis Coronary Heart Disease." In 2019 4th International Conference on Information Technology, Information Systems and Electrical Engineering (ICITISEE). IEEE, 2019. http://dx.doi.org/10.1109/icitisee48480.2019.9003746.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Coronary heart disease – Chemotherapy"

1

Dong, Guoqi, Mengye Lu, Xiaoliang Wu, Hao Chen, Hongru Zhang, and Yihuang Gu. Network meta-analysis of Traditional Chinese medicines for depression in coronary heart disease patients. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wienke, Andreas, Anne M. Herskind, Kaare Christensen, Axel Skytthe, and Anatoli I. Yashin. The influence of smoking and BMI on heritability in susceptibility to coronary heart disease. Rostock: Max Planck Institute for Demographic Research, January 2002. http://dx.doi.org/10.4054/mpidr-wp-2002-003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cai, Ruping, Yuli Xu, and Qiang Su. Meta-analysis of blood lipid reduction for patients with coronary heart disease by combination of pitavastatin and ezetimibe. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2021. http://dx.doi.org/10.37766/inplasy2021.5.0072.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ghambaryan, Anna. Heart Rate Variability, Catecholamine and Hemodynamic Responses During Rest and Stress in Coronary Artery Disease Patients: The PIMI Study. Fort Belvoir, VA: Defense Technical Information Center, January 2007. http://dx.doi.org/10.21236/ad1013978.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Pan, JianLue, Pangning Huang, Yuanwen Zhang, RongFa Huang, QiuCen Chen, and HuiBing Chen. Commonly Traditional Chinese Medicine in treatment of Coronary Atherosclerotic Heart Disease with Anxiety and Depression: a network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2021. http://dx.doi.org/10.37766/inplasy2021.4.0124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Liu, Chao, Jing Bai, Lanchun Liu, Jialiang Gao, and Jie Wang. Effectiveness and safety of Yufengningxin for treating coronary heart disease angina: A protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2020. http://dx.doi.org/10.37766/inplasy2020.11.0040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Wang, Lina, Yangli Sun, Jie Zhan, Zhiyuan Wu, Peiming Zhang, Xiaopeng Wen, Shuqi Ge, Xu Han, and Liming Lu. Effects of exercise therapy on anxiety and depression in patients with coronary heart disease: a meta-analysis of a randomized controlled study. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2021. http://dx.doi.org/10.37766/inplasy2021.6.0017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fan, Maoxia, Ying Tian, and Dong Guo. Efficacy and safety of Xinkeshu in the treatment of angina pectoris of coronary heart disease: A systematic review and meta-analysis protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0026.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Li, Xing-xing, Zong-jing Fan, Jie Cui, Rui Zhuang, Rong-peng Liu, Quan Lin, and Yang Wu. Cardiac rehabilitation of Baduanjin exercise in coronary heart disease after PCI: a protocol for systematic review and meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2021. http://dx.doi.org/10.37766/inplasy2021.3.0065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Xu, Xiangmei, Wenna Yang, Xuan Chen, Yixuan Kong, Jie Wang, and Jinghui Zheng. Traditional Chinese Medicine Injection Combined with Conventional Western Medicine in Treating Coronary Heart Disease after PCI:A Protocol systematic review and meta analysis of overview. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, July 2020. http://dx.doi.org/10.37766/inplasy2020.7.0087.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!